Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

April 11, 2011 - PRLog -- GlobalData has estimated the global endometrial cancer market to be valued at $137m in 2010. It is expected to grow to $179m with a Compound Annual Growth Rate (CAGR) of 3.91% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to the aging population, diabetes and obesity. The diagnosis and treatment seeking rate is also high in endometrial cancer. Currently there are no approved drugs for endometrial cancer and the market will be driven by the expected launch of the Ixempra (ixabepilone) in 2015.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Endometrial-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

GlobalData’s analysis found that the unmet need in the endometrial cancer market is high, which implies that the market is not well served with the current product options and there is some degree of scope available to launch new technology products that would capture value from under-served segments. Endometrial cancer is basically a surgically managed disease and there are no drugs approved for endometrial cancer. All the drugs that are currently used are generics and have high toxicity profiles. The response rates of these off-label drugs are high but the safety profile is low. Hence drugs with high efficacy and safety profiles will be able to fulfill the unmet need in the market as advanced and recurrent stages of the disease are treated with drug therapy only.

GlobalData’s analysis showed that there are 22 molecules in various stages of the pipeline. All the molecules in the pipeline have novel mechanisms, because of which the pipeline is strong. Research is prominent in the late phase of development, but the majority of the molecules are in Phase II, because of which their launch is not expected within the forecast period. Some of the promising molecules in late stage development are Ixempra, ridaforolimus, and XL147.

GlobalData, the industry analysis specialist, has released its new report, “Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global endometrial cancer therapeutics market. The report identifies the key trends shaping and driving the global endometrial cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometrial cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.


For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Endo...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.